Evidence comparison
How they actually compare on the evidence — trial volume, literature, mechanism, and our honest confidence grade. Higher counts reflect research attention, not proof of superiority.
Western · Flavonoid
槲皮素
Extensive human-trial evidence
Key active: Quercetin (flavonoid)
Early human senolytic trials (D+Q); anti-inflammatory data
Quercetin modulates inflammation and, combined with dasatinib (D+Q), is the most-studied senolytic regimen in early human trials for senescence-associated conditions.
Full Quercetin evidence →Western · Flavonoid
芹菜素
Human RCT evidence
Key active: Apigenin (flavone — CD38 inhibitor & SIRT1 modulator)
Strong preclinical (CD38/NAD+/SIRT1); human cancer/anti-inflammatory trials
Apigenin inhibits CD38, an ectoenzyme that consumes ~60% of cellular NAD+. This creates mechanistic synergy with NMN/NR: more precursor + less degradation. Apigenin also modulates SIRT1, CK2, and NF-κB. Most longevity evidence is preclinical; anti-cancer and anti-inflammatory human trials are ongoing.
Full Apigenin evidence →Need this for a decision?
We build evidence-graded comparisons for formulators, brands, clinics, and investors.
Informational only — not medical advice or a recommendation to take either. Trial and literature counts are registry/database matches and include endpoints beyond longevity. See each ingredient page for sources.